Paul Thomen

Wednesday, 20 March 2013

Global Pandemic Control Markets and Technologies

The report provides:

- An overview of the products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS
- Analyses of market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Clarification of the HIV/AIDS pandemic and ongoing efforts to control it
- Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases
- Trends based on projected sales through 2017 for new products, including supporting analyses for projections.
- Comprehensive company profiles of major players.

Reasons for Doing the Study

The spread of human immunodeficiency virus (HIV), hepatitis B and C, evolving influenza strains and antibiotic-resistant organisms have put healthcare agencies on guard to avert pending pandemics from these diseases. They have also alerted healthcare professionals to the possibility of the use of viruses and bacteria in bioterrorism threats.

The problem of antimicrobial resistance poses a global threat to the effective treatment of many bacterial diseases. Additionally, the emergence of drug-resistant strains of HIV and hepatitis have jolted the healthcare community out of its relative complacency about the threat of infectious diseases and prompted diagnostic and pharmaceutical manufacturers to bolster their infectious disease pipelines.
Multidrug-resistant tuberculosis is no longer confined to any one country or to those individuals who are co-infected with HIV. A number of multidrug resistant microbes such as methicillin-resistant Staphalococcus auerus (MRSA) and vancomycin-resistant Enterococcus (VRE) that were once found only in hospitals or nursing homes are now active in the community at large.

The rate of HIV infection combined with resistance to existing HIV and acquired immunodeficiency syndrome (AIDS) drugs and the obstacles encountered in developing an AIDS vaccine have resulted in a full-blown pandemic. Further, drug resistance in the treatment of HIV/AIDS necessitates the use of complex dosage protocols with unpleasant side effects that often further debilitate patients.
Solutions to the dilemma of drug resistance involve management approaches on a worldwide scale (such as the implementation of rigorous surveillance of resistant organisms), better education of healthcare workers about appropriate use of antibiotics and closer monitoring of antibiotics used in animal and plant crops.

Combined with these organizational activities is the need for new and effective drugs. New drugs to treat bacterial diseases and HIV/AIDS are being developed, but a new class of drugs to treat bacterial infections has not been developed since 2003, underscoring the need for more development in this area.

Scope Of Report

This report provides an in-depth look at the emerging pandemic of antibiotic resistance and the established viral pandemic of HIV/AIDS. It also provides historical, epidemiological and market information on hepatitis B and C, tuberculosis and malaria. This report also investigates bacterial and viral diseases that are emerging as health threats because of inadequate or nonexistent preventive and/or therapeutic products to combat them.

Antibiotic-resistant organisms wreak havoc with international healthcare systems as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and Clostridium difficile (C. diffile) become more pervasive. These infections represent future pandemics if no suitable antibiotics are developed to counteract them. At present, each is problematic, but remains at an epidemic level, primarily within healthcare institutions and nursing facilities. Consequently, these infections are covered descriptively within the report, but are not yet classified as pandemics, nor measured quantitatively as part of the overall market for pandemics.

The report outlines the available preventative and diagnostic products used to combat current and future pandemic infections and projects markets for these products. Forecasts are provided for the diagnostic and pharmaceutical markets for products to treat HIV/AIDS, hepatitis B and C, malaria and tuberculosis. Forecasts and trends are gleaned from industry sources as well as from an assessment of emerging products and technologies.

The causes, the extent of impact and strategies to monitor, treat and prevent resistant diseases are assessed. The mechanisms by which drugs function to combat resistant microbes are described. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effects on the market are assessed.

Methodology/Information Sources

The data for this report were gathered from primary and secondary sources, including information obtained from industry analysts, manufacturer and company reports, industry trade journals, medical journals and industry associations. Additional information was obtained through the U.S. Patent and Trademark Office (USPTO), U.S. Securities and Exchange Commission (SEC) filings, The World Health Organization (WHO), the Organisation for Economic Cooperation and Development (OECD), the Mayo Clinic, the Pharmaceutical Research and Manufacturing Association and the Joint United Nations Programme on HIV/AIDS (UNAIDS).

Where precise information was not available, projections were made using reasonable assumptions and estimates based on historical data. Market data are based on manufacturers’ sales.

Table of Content

Chapter- 1: Introduction
Reasons for Doing the Study
Scope of Report
Methodology/Information Sources
Intended Audience
Analyst Credentials
Related Bcc Reports
Bcc Online Services
Chapter- 2: Summary
Table Summary : Projected Market for Pandemic Infectious Disease Products, by Disease Type, Through 2017
Figure Summary : Projected Market for Pandemic Infectious Disease Products, by Region, 2012 and 2017
Chapter- 3: Overview
Pathogenic Microbes and Infectious Diseases Recognized Between 1973 and 2009
Factors In the Emergence of Infectious Diseases
Antibiotic Development
Classifying Viral Outbreaks, Epidemics and Pandemics
Current and Potential Epidemics With Pandemic Potential
Current and Potential Pandemics
Current Technologies for Addressing Potential Pandemic Threats
Biological Weapons for Terrorism
A Brief History of Global Pandemics
Treatments for Infectious Diseases
Opportunities to Fight Potential Pandemic Infectious Diseases
Bioinformation and Remote Sensing Market
Mergers and Acquisitions
Chapter- 4: Vaccines, Diagnostic Testing, and Pharmaceutical Markets for Infectious Diseases
Types of Diagnostic Testing
Market Analysis, by Disease
Chapter- 5: Disease Overview
Hepatitis B and C
Severe Acute Respiratory Syndrome (Sars)
Hemorrhagic Fevers
Table 27 : Causative Organisms for Pandemic Diseases
Chapter- 6: Viral Pandemic Threats and Treatments
What Is A Virus?
Projected Global Market for Vaccines, Diagnostics and Pharmaceuticals
Global Diagnostic Market for Hiv and Hepatitis
Market for Viral Disease Diagnostic Products
Viral Pandemic Pharmaceutical Products, by Disease
Regional Analysis
Opportunities In the Viral Pandemic Infectious Disease Diagnosis and Treatment Market
Chapter- 7: Bacterial Pandemic Threats and Treatments
Antibacterial Resistance
Primary Reasons for Antibiotic Resistance
Surveillance of Microbial Resistance to Antibiotics
Resistance by Class of Antibiotic
Incidences of Antibiotic Resistance
Vancomycin-Resistant Enterococcus (Vre)
Methicillin-Resistant Staphylococcus Aureus (Mrsa)
Clostridium Difficile (C. Difficile)
Tuberculosis (Tb)
Regional Analysis
Opportunities In the Tuberculosis Market
Chapter- 8: Parasitic Pandemic Threats and Treatments
Climate Change and Vector-Borne Diseases
Chapter- 9: Regulations
Creating Drug Treatments
Regional Regulations
Chapter- 10: Pharmaceutical Treatment Pipeline
Emerging Trends In Diagnostic Products
Emerging Trends In Pharmaceutical Products
Pharmaceutical Treatment Product Pipeline
Chapter- 11: Patent Analysis
Pharmaceutical Patents Issued by Company, Approval Date and Disease
Diagnostic Patents Issued by Company, Approval Date and Disease
Patents Issued by Company
Patents Issued by Country
Patents Issued, by Disease
Chapter- 12: Company Directory
Abbott Laboratories
Alfa Scientific Designs
Anadys Pharmaceuticals (See Roche)
Atlas Link Biotech Co, Ltd
Baxter Healthcare
Bayer Ag
Bio-Rad Laboratories
Boehringer Ingelheim Gmbh
Bristol-Myers Squibb Company
Creative Diagnostics
Diagnostic Automation/Cortez Diagnostics, Inc
Emergent Biosolutions
Enanta Pharmaceuticals
Enzo Biochem
First Diagnostic Llc
Gilead Sciences, Inc.
Home Access Health, Inc
Human Genome Sciences (See Glaxosmithkline)
Idenix Pharmaceuticals
Ind Diagnostic, Inc.
Inverness Medical Innovations (See Alere)
Janssen Therapeutics (Formerly Tibotec Therapeutics)
Merck & Company, Inc.
Novartis Pharmaceutical Corporation
Orasure Technologies, Inc.
Ortho Clinical Diagnostics
Pfizer, Inc.
Princeton Biomeditech Corporation
Protein Sciences Corporation
Roche Laboratories (Hoffmann-La Roche Inc)
Rib-X Pharmaceuticals
Romark Laboratories
Sanofi Pasteur
Sciclone Pharmaceuticals
Shanghai Kehua Bio-Engineering Co, Ltd
Standard Diagnostics, Inc
Trinity Biotech Plc
Vertex Pharmaceuticals
Viiv Healthcare

No comments:

Post a Comment

Note: only a member of this blog may post a comment.